Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.

ABSTRACT:

Background

Numerous first-line immune checkpoint inhibitors (ICI) were developed for patients with advanced non-small cell lung cancer (NSCLC) lacking driver gene mutations. However, this group consists of a heterogeneous patient population, for whom the optimal therapeutic choice is yet to be confirmed.

Objective

To identify the best first-line immunotherapy regimen for overall advanced NSCLC patients and different subgroups.

Design

Systematic review and Bayesian network meta-analysis (NMA).

Methods

We searched several databases to retrieve relevant literature. We performed Bayesian NMA for the overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (tr-AEs) with a grade equal or more than 3 (

SUBMITTER: Wenfan F 

PROVIDER: S-EPMC10568994 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature